GSE216273 GSE216292 palbociclib 14 v 1 human dn (Gene Set)

Analyze

Playbook Workflow Builder
Playbook Workflow Builder: Gene Set Enrichment

Perform Gene Set Enrichment with this gene set against Common Fund program's gene sets, identifying significant overlaps using a pre-built PWB workflow. Run the workflow with GSE216273_GSE216292_palbociclib_14_v_1_human_dn.

GeneSetCart
GeneSetCart

GeneSetCart helps you to fetch gene sets from various data sources, augment, combine with set operations, visualize and analyze these gene sets in a single session. Start a new session with GSE216273_GSE216292_palbociclib_14_v_1_human_dn.

CFDE-GSE
CFDE Gene Set Enrichment (GSE)

CFDE-GSE illuminates connections between the input gene set and various CF gene sets that overlap with the queried gene set. Query CFDE-GSE with GSE216273_GSE216292_palbociclib_14_v_1_human_dn.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with GSE216273_GSE216292_palbociclib_14_v_1_human_dn.

Results found

Linked to

 

Label

Description

 

Gene

MIR4435-2 host gene

Gene

MSL complex subunit 3B

Gene

cytoskeleton regulator RNA

Gene

POU class 3 homeobox 3

Gene

Gfo/Idh/MocA-like oxidoreductase domain containing 3, pseudogene

Gene

cutA divalent cation tolerance like, pseudogene

Gene

zinc finger protein 839 pseudogene

Gene

HERPUD2 antisense RNA 1

Gene

uncharacterized LOC339260

Gene

HOX transcript antisense RNA


  • Gene

    MSL complex subunit 3B


  • Gene

    cytoskeleton regulator RNA


  • Gene

    POU class 3 homeobox 3


  • Gene

    Gfo/Idh/MocA-like oxidoreductase domain containing 3, pseudogene


  • Gene

    cutA divalent cation tolerance like, pseudogene


  • Gene

    zinc finger protein 839 pseudogene


  • Gene

    HERPUD2 antisense RNA 1


  • Gene

    uncharacterized LOC339260


  • Gene

    HOX transcript antisense RNA

  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.